Moreover, with the recent remarkable advances in chemotherapy drugs and strategies, the reported survival of NSCLC patients with distant metastasis has been improving (3), especially for the patients with adenocarcinoma that harbors sensitive driver oncogene mutations or fusion, such as epidermal growth factor receptor (EGFR) (4) and anaplastic lymphoma kinase (ALK) (5). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.